A detailed history of Valley National Advisers Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Valley National Advisers Inc holds 47,155 shares of GILD stock, worth $4.31 Million. This represents 0.71% of its overall portfolio holdings.

Number of Shares
47,155
Previous 90,854 48.1%
Holding current value
$4.31 Million
Previous $6.23 Million 36.59%
% of portfolio
0.71%
Previous 0.92%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$66.59 - $83.99 $2.91 Million - $3.67 Million
-43,699 Reduced 48.1%
47,155 $3.95 Million
Q2 2024

Jul 18, 2024

SELL
$63.15 - $72.88 $447,291 - $516,209
-7,083 Reduced 7.23%
90,854 $6.23 Million
Q1 2024

Apr 19, 2024

SELL
$71.58 - $87.29 $263,128 - $320,878
-3,676 Reduced 3.62%
97,937 $7.17 Million
Q4 2023

Jan 25, 2024

SELL
$73.27 - $83.09 $444,968 - $504,605
-6,073 Reduced 5.64%
101,613 $8.23 Million
Q3 2023

Nov 13, 2023

SELL
$73.94 - $80.67 $494,510 - $539,520
-6,688 Reduced 5.85%
107,686 $8.07 Million
Q2 2023

Jul 31, 2023

SELL
$76.01 - $86.7 $516,868 - $589,560
-6,800 Reduced 5.61%
114,374 $8.82 Million
Q1 2023

Apr 26, 2023

SELL
$77.31 - $88.08 $157,867 - $179,859
-2,042 Reduced 1.66%
121,174 $10.5 Million
Q4 2022

Jan 12, 2023

SELL
$62.32 - $89.47 $141,279 - $202,828
-2,267 Reduced 1.81%
123,216 $10.7 Million
Q3 2022

Nov 08, 2022

BUY
$59.54 - $68.01 $146,766 - $167,644
2,465 Added 2.0%
125,483 $8.39 Million
Q2 2022

Jul 15, 2022

BUY
$57.72 - $65.01 $555,497 - $625,656
9,624 Added 8.49%
123,018 $7.72 Million
Q1 2022

May 06, 2022

BUY
$57.92 - $72.58 $2.27 Million - $2.84 Million
39,186 Added 52.81%
113,394 $6.74 Million
Q4 2021

Feb 11, 2022

BUY
$64.88 - $73.64 $773,758 - $878,230
11,926 Added 19.15%
74,208 $5.39 Million
Q3 2021

Nov 10, 2021

BUY
$67.69 - $73.03 $569,949 - $614,912
8,420 Added 15.63%
62,282 $4.35 Million
Q2 2021

Aug 02, 2021

BUY
$63.47 - $69.35 $933,389 - $1.02 Million
14,706 Added 37.56%
53,862 $3.71 Million
Q1 2021

May 07, 2021

BUY
$60.0 - $68.46 $2.27 Million - $2.59 Million
37,874 Added 2954.29%
39,156 $2.53 Million
Q4 2020

Feb 11, 2021

SELL
$56.65 - $64.55 $1,472 - $1,678
-26 Reduced 1.99%
1,282 $75,000
Q2 2020

Aug 10, 2020

BUY
$72.34 - $84.0 $5,425 - $6,300
75 Added 6.08%
1,308 $101,000
Q1 2020

May 13, 2020

SELL
$62.63 - $80.22 $313 - $401
-5 Reduced 0.4%
1,233 $92,000
Q3 2019

Nov 12, 2019

SELL
$62.51 - $69.0 $6,251 - $6,900
-100 Reduced 7.47%
1,238 $78,000
Q2 2019

Aug 08, 2019

SELL
$61.87 - $69.38 $4,825 - $5,411
-78 Reduced 5.51%
1,338 $90,000
Q1 2019

Apr 26, 2019

SELL
$62.53 - $70.05 $2,751 - $3,082
-44 Reduced 3.01%
1,416 $92,000
Q4 2018

Feb 25, 2019

SELL
$60.54 - $79.0 $8,838 - $11,534
-146 Reduced 9.09%
1,460 $91,000
Q3 2018

Nov 08, 2018

SELL
$71.28 - $78.92 $784 - $868
-11 Reduced 0.68%
1,606 $124,000
Q2 2018

Aug 14, 2018

BUY
$64.88 - $75.68 $2,530 - $2,951
39 Added 2.47%
1,617 $115,000
Q3 2017

Nov 14, 2017

BUY
$72.11 - $85.47 $113,789 - $134,871
1,578
1,578 $128,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Valley National Advisers Inc Portfolio

Follow Valley National Advisers Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Valley National Advisers Inc, based on Form 13F filings with the SEC.

News

Stay updated on Valley National Advisers Inc with notifications on news.